Literature DB >> 27405774

Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.

Gerrit Frommeyer1, Henning von der Ahe2, Benedict Brücher2, Dirk G Dechering2, Philipp S Lange2, Florian Reinke2, Kristina Wasmer2, Julia Köbe2, Christian Pott2, Gerold Mönnig2, Lars Eckardt2.   

Abstract

In several case reports, proarrhythmic effects of antipsychotic drugs have been reported. The aim of the present study was to investigate if application of risperidone or quetiapine has the potential to provoke polymorphic ventricular tachycardia in a sensitive model of proarrhythmia. In 24 isolated rabbit hearts, risperidone (5 and 10 μM, n = 12) or quetiapine (5 and 10 μM, n = 12) was infused after obtaining baseline data. Eight endocardial and epicardial monophasic action potentials and a simultaneously recorded 12-lead ECG showed a significant QT prolongation after application of risperidone as compared with baseline (5 μM: +29 ms, 10 μM: +35 ms, p < 0.01) accompanied by an increase of action potential duration. Administration of risperidone also significantly increased spatial dispersion of repolarization (5 μM: +16 ms, 4 μM: +19 ms; p < 0.05) as well as temporal dispersion of repolarization. Lowering of potassium concentration in bradycardic AV-blocked hearts provoked early afterdepolarizations (EADs) in 8 of 12 hearts and polymorphic ventricular tachycardia resembling torsade de pointes in 6 of 12 hearts (10 μM, 49 episodes). The results were compared with hearts treated with quetiapine (5 and 10 μM). Quetiapine led to an increase in QT interval (5 μM: +10 ms; 10 μM: +28 ms; p < 0.05) and a similar increase of APD90. However, treatment with quetiapine did not result in significant alterations of spatial and temporal dispersion of repolarization. No ventricular arrhythmias were observed in this group. In the present study, quetiapine demonstrated a safe electrophysiologic profile despite significant QT prolongation. In contrast, risperidone led to a more marked prolongation of myocardial repolarization combined with a more marked increase of dispersion of repolarization.

Entities:  

Keywords:  Dispersion of repolarization; Polymorphic ventricular tachycardia; Proarrhythmia; Quetiapine; Risperidone; Sudden cardiac death

Mesh:

Substances:

Year:  2016        PMID: 27405774     DOI: 10.1007/s00210-016-1274-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.

Authors:  L M Hondeghem; L Carlsson; G Duker
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.

Authors:  W V R Vieweg; R K Schneider; M A Wood
Journal:  Acta Psychiatr Scand       Date:  2005-10       Impact factor: 6.392

3.  Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I.

Authors:  Tomas Raviña; Paula Raviña; Javier Gutierrez
Journal:  Int J Cardiol       Date:  2006-07-26       Impact factor: 4.164

4.  Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L).

Authors:  Torsten Christ; Erich Wettwer; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-06-16       Impact factor: 3.000

5.  A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.

Authors:  Gerrit Frommeyer; Peter Milberg; Patricia Witte; Jörg Stypmann; Matthias Koopmann; Martin Lücke; Nani Osada; Günter Breithardt; Michael Fehr; Lars Eckardt
Journal:  Eur J Heart Fail       Date:  2011-08-25       Impact factor: 15.534

6.  Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.

Authors:  Peter Milberg; Lars Eckardt; Hans-Jürgen Bruns; Julia Biertz; Shahram Ramtin; Nico Reinsch; Dirk Fleischer; Paulus Kirchhof; Larissa Fabritz; Günter Breithardt; Wilhelm Haverkamp
Journal:  J Pharmacol Exp Ther       Date:  2002-10       Impact factor: 4.030

7.  Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.

Authors:  Srihari Gopal; David Hough; Keith Karcher; Isaac Nuamah; Joseph Palumbo; Jesse A Berlin; Alan Baseman; Yimei Xu; Justine Kent
Journal:  J Clin Psychopharmacol       Date:  2013-04       Impact factor: 3.153

8.  Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control.

Authors:  S C Verduyn; M A Vos; J van der Zande; A Kulcsàr; H J Wellens
Journal:  J Am Coll Cardiol       Date:  1997-11-15       Impact factor: 24.094

9.  Vernakalant in an experimental model of pacing-induced heart failure: lack of proarrhythmia despite prolongation of repolarization.

Authors:  Gerrit Frommeyer; Jochen Schulze Grotthoff; Christina Fischer; Harilaos Bogossian; Florian Reinke; Simon Kochhäuser; Dirk G Dechering; Michael Fehr; Peter Milberg; Lars Eckardt
Journal:  J Card Fail       Date:  2014-07-30       Impact factor: 5.712

Review 10.  Experimental models of torsade de pointes.

Authors:  L Eckardt; W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Res       Date:  1998-07       Impact factor: 10.787

View more
  1 in total

1.  Transgenic LQT2, LQT5, and LQT2-5 rabbit models with decreased repolarisation reserve for prediction of drug-induced ventricular arrhythmias.

Authors:  Tibor Hornyik; Alessandro Castiglione; Gerlind Franke; Stefanie Perez-Feliz; Péter Major; László Hiripi; Gideon Koren; Zsuzsanna Bősze; András Varró; Manfred Zehender; Michael Brunner; Christoph Bode; István Baczkó; Katja E Odening
Journal:  Br J Pharmacol       Date:  2020-06-24       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.